logo-loader
viewEnvisagenics

Envisagenics using SpliceCore platform and A.I. to find hidden cures faster

Envisagenics, Inc CEO Maria Luisa Pineda sat down with Proactive’s Christine Corrado at BIO CEO in New York. The New York-based biotechnology company is leveraging artificial intelligence and RNA-splicing analytics for discovery and development of disease-specific therapeutics. The privately-held company was recently awarded a Small Business Innovation Research (SBIR) Phase I grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH). 

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Morning Report: FTSE 100 opens in red ahead of US job numbers; Bail-out for...

Headlines from the Proactive UK newsroom. London’s leading shares are set to open on the back foot this morning ahead of the release later of US jobs figures for March.. But economists say the full scale of the rising jobless in the US economy will be revealed in next month’s...

18 hours, 5 minutes ago

2 min read